The emerging role of cytokines in the treatment of advanced melanoma

被引：24

作者：

Keilholz, U

Eggermont, AMM

机构：

[1] Free Univ Berlin, Hosp Benjamin Franklin, Dept Med 3, D-1000 Berlin, Germany

[2] Dr Daniel Den Hoed Canc Ctr, Dept Surg Oncol, NL-3008 AE Rotterdam, Netherlands

来源：

ONCOLOGY | 2000年 / 58卷 / 02期

关键词：

melanoma; interferon-alpha; interleukin-2; chemo-immunotherapy; EORTC;

D O I：

10.1159/000012085

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cytokine-based treatment regimens have been evaluated for advanced melanoma in a number of phase I and phase II trials within the last decade. Treatment with interleukin-2 (IL-2) as a single agent has resulted in response rates of approximately 15%, if a high dose of IL-2 is administered. Combination of interferon-alpha (IFN alpha) and high dose IL-2 yields response rates ranging from 10 to 41%, Response rates exceeding 50% have been reported with chemoimmunotherapy, if the treatment regimens included at least the three agents IL-2, IFN alpha and cisplatin, Recent randomized trials have evaluated the impact of these drugs on the survival of patients with advanced melanoma. The current 'state of the art' is discussed in this review, Copyright (C) 2000 S. Karger AG, Basel

引用

页码：89 / 95

页数：7

共 57 条

[11]

DORVAL T, 1991, EUR J CANC S2, V27, pS99

[12]

DUMMER R, 1995, CANCER, V75, P945

[13] IMPROVED RESULTS WITH THE ADDITION OF INTERFERON ALFA-2B TO DECARBAZINE IN THE TREATMENT OF PATIENTS WITH METASTATIC MALIGNANT-MELANOMA [J].

FALKSON, CI ;

FALKSON, G ;

FALKSON, HC .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) :1403-1408

[14] Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma:: An Eastern Cooperative Oncology Group study [J].

Falkson, CI ;

Ibrahim, J ;

Kirkwood, JM ;

Coates, AS ;

Atkins, MB ;

Blum, RH .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1743-1751

[15]

FLAHERTY LE, 1993, CANCER, V71, P3520, DOI 10.1002/1097-0142(19930601)71:11<3520::AID-CNCR2820711110>3.0.CO

[16]

2-A

[17]

FLAHERTY LE, 1990, CANCER-AM CANCER SOC, V65, P2471, DOI 10.1002/1097-0142(19900601)65:11<2471::AID-CNCR2820651113>3.0.CO

[18]

2-F

[19]

GIACOMINI P, 1984, J IMMUNOL, V133, P1649

[20] Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1•5 mm without clinically detectable node metastases [J].

Grob, JJ ;

Dreno, B ;

de la Salmonière, P ;

Delaunay, M ;

Cupissol, D ;

Guillot, B ;

Souteyrand, P ;

Sassolas, B ;

Cesarini, JP ;

Lionnet, S ;

Lok, C ;

Chastang, C ;

Bonerandi, JJ .

LANCET, 1998, 351 (9120) :1905-1910

← 1 2 3 4 5 6 →